Podcasts about MRC

Maurice Kamto a démissionné avant-hier de son poste de président du Mouvement pour la renaissance du Cameroun (MRC), formation qu'il dirigeait depuis 13 ans. Démission également du vice-président Mamadou Mota. « Cette démission de Maurice Kamto, explique Jeune Afrique, intervient alors que le MRC est englué dans plusieurs procédures judiciaires et que sa participation aux prochaines élections locales est remise en question, en raison d'un potentiel conflit avec le ministère de l'Administration territoriale. Et la formation se déchire dans des querelles autour de la légitimité de son leadership depuis des semaines. » Les prochaines élections législatives et municipales au Cameroun doivent avoir lieu l'année prochaine. Et Maurice Kamto, pointe Jeune Afrique, est « déterminé à ce que le MRC se présente à ces scrutins, après le boycott opéré lors des précédentes élections en 2020. L'opposant en exil Issa Tchiroma Bakary a annoncé que ni lui ni son parti, le Front pour le salut national du Cameroun, ne prendront part à ces élections, ce qui place le MRC dans le fauteuil de principal adversaire du RDPC, au pouvoir. Maurice Kamto n'a sans doute pas souhaité hypothéquer ce duel à venir, lequel pourrait le replacer comme principal adversaire du président Paul Biya ». À lire aussiCameroun : l'opposant Maurice Kamto démissionne de la présidence du MRC, Mamadou Mota quitte la vice-présidence Le MRC en ordre de bataille pour 2027 ? Alors, ce départ est-il destiné à donner un nouvel élan à son parti ? Sans doute, estime WakatSéra au Burkina : « La pression de l'administration étant devenue trop forte contre sa personne, Maurice Kamto n'avait d'autre option pour donner une chance de survie à sa formation politique que de rendre le tablier. Et c'est pour ne pas saborder les chances du MRC, qui entend se mettre en ordre de bataille pour les prochaines élections de 2027, que le président et le premier vice-président ont quitté leurs postes. Une stratégie qui pourrait bien être payante si une nouvelle convention est tenue bientôt, comme le prévoit le parti. » Reste, tempère WakatSéra, que « l'avenir ne s'annonce pas des plus roses pour le MRC tout comme pour les autres partis d'opposition, le Cameroun de Paul Biya étant une terre plus ou moins hostile à quiconque refusant de marcher dans la direction du vent. Comme dans bien des pays sur le continent, l'opposition n'y est tolérée que lorsqu'elle ne… s'oppose pas au pouvoir. Et le MRC doit trouver la stratégie pour non seulement continuer à exister, mais chercher à conquérir le pouvoir d'État, conformément à ses objectifs de parti d'opposition ! ». En position de force… Pour le journaliste et analyste Albin Djilo, cité par le site Actu Cameroun, avec cette stratégie, « Maurice Kamto est capable de surprendre ses adversaires et de rebattre les cartes politiques. Le RDPC, le parti au pouvoir, a, semble-t-il, choisi de reproduire le scénario de 2025, affirme Albin Djilo, en misant sur l'instrumentalisation de certains membres du MRC pour, au final, tenter de suspendre la participation du parti aux élections locales. Le régime démontre ainsi, aux yeux d'une partie de l'opinion, poursuit le journaliste camerounais, qu'il considère Maurice Kamto comme son principal adversaire politique. Une situation qui pourrait finalement faire le jeu de Kamto dans un pays où le bilan du régime suffit déjà à faire du simple rejet du système un puissant moteur électoral ». … ou à bout de force ? Enfin, une autre interprétation du départ de Kamto de la présidence de son parti pourrait être tout simplement… la lassitude. C'est du moins ce qu'avance L'Observateur Paalga : « Sa vie d'opposant a été marquée par des bras de fer permanents avec le pouvoir de Yaoundé, alternant succès populaires, sévères déboires judiciaires et politiques et résidences surveillées. […] Alors, peut-on parler de lassitude ? Peut-être que oui. […] Une chose est certaine, pointe encore le site burkinabè : le départ de Maurice Kamto ouvre une nouvelle période d'incertitude pour le MRC et soulève une question essentielle : s'agit-il d'un retrait tactique destiné à sauver le parti, ou du geste d'un homme arrivé au bout de ses forces dans son interminable bras de fer avec le pouvoir de Yaoundé ? »

Send us Fan MailIn this episode of the WTR Small Cap Spotlight, WTR Managing Director for Natural Resources Jeff Robertson joins Tim Gerdeman to assess the second half of 2026 and early 2027 budget outlooks for the U.S. energy sector. The conversation covers how producers are managing continued oil price volatility driven by the Iran conflict and Strait of Hormuz disruptions, with WTI averaging $81.25 in Q3 and futures pointing toward the low $70s through 2027.Robertson walks through WTR's oilfield services coverage, addressing Select Water Solutions' water infrastructure margin expansion story, DNOW's MRC integration progress and path to $350 million EBITDA, and international opportunities for National Energy Services Reunited and Forum Energy Technologies across the Middle East, Argentina, and Venezuela.The episode also covers WTR's U.S. producer universe, including Riley Exploration Permian, Ring Energy, HighPeak Energy, Evolution Petroleum, Prairie Operating, and W&T Offshore, as well as Africa-focused Meren Energy and VAALCO Energy, where development drilling campaigns in Nigeria, Gabon, and Cote d'Ivoire are positioned to drive production growth into 2027.Robertson closes with takeaways from the EnerCom Conference and a preview of the WTR Virtual Insights Conference on September 22 to 23. For additional content, visit www.watertowerresearch.com.

MRC finishes up February 1969 with Captain America 110 (Steranko!), Iron Man 10, Doctor Strange 177 and 178 and Avengers 61. We had to double up on Doctor Strange because they both take place before this month's Avengers, so you get two!

In this episode of Behind the Genes, we explore how personalised cancer vaccines are being developed, and how genomics and AI could help make these treatments more precise.  Our host, Florence Cornish is joined by:  Dr Victoria Goss, Associate Professor of Early Diagnosis and Translational Research at Southampton Clinical Trials Unit and head of the Southampton Clinical Trials Unit Cancer Vaccine Launchpad team  Professor Lennard Lee, Associate professor at the University of Oxford, Consultant Medical Oncologist, NHS  Ali Richards, a participant who took part in a cancer vaccine clinical trial  Together they discuss how cancer vaccines train the immune system to recognise cancer, how genomic information can help identify the unique features of an individual's tumour, and how AI could help researchers analyse genomic data and accelerate the development of new cancer vaccines.   “The reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through.”    Transcript [00:00:00] Florence: What if a vaccine could help treat cancer? Hello and welcome to Behind the Genes, the podcast that brings you the stories, research, and innovations shaping the future of genomic healthcare. Today, we're going to be talking about cancer vaccines, how they're being developed with the help of AI, what role genomics has to play, and what it could mean for patients.  [00:00:23] Florence: I'm Florence Cornish, and joining me today we have Dr Victoria Goss, who leads cancer vaccine research at Southampton Clinical Trials Unit; we have Professor Lennard Lee, who is a medical oncologist and Associate Professor at the University of Oxford; and Ali Richards, who took part in the Southampton Cancer Vaccine Programme.  [00:00:45] Florence: I think before we get into cancer vaccines specifically, it might be good to start with the basics. So vaccines are something most of us have heard of and probably experienced as well, but we don't always necessarily understand how they work. So Lennard, can I come to you to explain what a vaccine actually is, how it works with our immune system, maybe at the most basic level for those who might not have a scientific background?  [00:01:19] Lennard: Thanks, Florence. What's a vaccine? Very, very simply, something that protects your body from disease. We've had a few when we were younger, like which protects you against meningitis or hepatitis or different types of infections that can affect children.  [00:01:36] Lennard: And it really does show that your immune system is really powerful. Every day, it looks around trying to work out what's there which shouldn't be there and takes care of it. And ideally, your immune system just works in the background without causing any problems. And so what a vaccine does is it really helps the body understand something that's abnormal.  [00:01:55] Lennard: And the vision here is that you can use this technology to hopefully patrol against cancer, because half the people out there will never get cancer. They are the maybe the lucky ones or maybe the ones with a good immune response. And so a vaccine is basically giving your immune system a wanted poster:  [00:02:11] Lennard: "This is what threat looks like. This is what you need to control".   [00:02:16] Florence: And I think you mentioned some great examples there. There are lots of common examples of vaccines people might have heard of. I think maybe the flu vaccine is probably a common one that people are thinking about in the wintertime. I think another one is maybe the HPV vaccine.  [00:02:29] Florence: Lennard, could you explain a bit more to our listeners about the HPV vaccine? What it is, how it works? I think people often think of it as a type of cancer vaccine, but actually it's targeting a virus. Is that right?   [00:02:41] Lennard: Yeah, that's correct. So this is now a vaccine which has been rolled out across the NHS, and it's actually worked really well to get rid of a few cancer types, which is incredible.  [00:02:51] Lennard: And why is that important? Well, cancer can be caused by many, many different things. Sometimes it's because you've done things like smoking or weight plays a role or just bad luck or the genes that you've inherited. But some cancer types are caused by viruses. And so many people nowadays are getting the HPV vaccine to stop cancer types like cervical cancer, hopefully head and neck cancer, and many of the rarer cancer types.  [00:03:21] Lennard: And so again, what you're doing here is you're taking the immune response, telling it the body shouldn't get this virus and hopefully prevent some of the bad consequence of getting this viral infection, like cancers.   [00:03:33] Florence: Thank you. That's really helpful to understand. So we've talked about how vaccines can be used to treat viruses, and I think most of us, when we hear the word ‘vaccine', we probably do associate it with something that stops us from getting ill.  [00:03:46] Florence: Victoria, could you tell us about how vaccines could be used to treat cancer?   [00:03:50] Victoria: Yeah, absolutely, and it is great to be here today. Thank you. So Lennard's already sort of spoken about preventative vaccines, and when we think about cancer vaccines, we're thinking about therapeutic vaccines. So we're thinking about training the immune system to recognise the cancer as something that needs to be dealt with because cancer is really tricky because it's our own cells that have gone wrong, if you like.  [00:04:16] Victoria: But that means it also is very good at evading those signals which tell the immune system that it needs to be cleared. So the analogy that Lennard has already given of a cancer vaccine sort of creating a wanted poster sort of builds on an analogy from one of your previous podcasts where they described the immune system as like the police almost trying to catch criminals, which are the cancer cells.  [00:04:41] Victoria: And the cancer vaccine analogy builds on that. So you've created a wanted poster which is training and giving the police more information about what those cancer cells look like. And then when we think about building on that with sort of personalised cancer vaccines, which is an incredibly exciting step when we think about the development of how cancer vaccines can be used, sort of really individualised therapy going forward, that wanted poster gets even more specific.  [00:05:07] Victoria: It's almost like giving a phone number or an address for that specific cancer type that is very specific to that patient. So the therapeutic vaccine is, is targeting the immune system. It's training our immune system to recognise the cancer as something that needs to be dealt with.   [00:05:26] Florence: It's funny you mentioned that analogy because I was just about to point listeners to that episode. If anyone wants to learn more about cancer vaccines specifically, you can check out our previous Genomics 101 podcast episode called ‘What Are Cancer Vaccines?' So Ali, I think I'd love to bring you in at this point because you have experienced this from the patient side of things.  [00:05:49] Florence: Could you tell us a little bit about your journey, your cancer diagnosis and treatment, and maybe more about the clinical trial you were part of, if you feel comfortable sharing that?   [00:05:57] Ali: Yeah, sure. Hi, Florence. It was Christmas 2015, and I felt a lump in my neck. And maybe because I'm a woman and we're always taught to treat lumps seriously, in the January I made an appointment with the GP, and she very quickly fast-tracked me through to the hospital.  [00:06:19] Ali: And January 2016, I got a diagnosis. It was a tumour on the base of my tongue at the left, and I was told it was caused by a variation of the HPV virus. So yeah, that was all a bit of a shock. I was shocked and I was scared, but I was also really angry because I look after myself. I eat well, all those things.  [00:06:45] Ali: It's just bad luck that it was a virus that my body couldn't deal with. I just, I felt guilty as well because of what I was gonna put the family through. So I had various scans and tests. I had an operation to remove my tonsils, although we soon discovered there weren't any left anyway. And they took a biopsy, which I didn't know at the time, but turned out to be important later on for the trial.  [00:07:15] Ali: Then I had to have a whole load of prep beforehand because of the impact of the treatment. So I had to have restorative dentistry, audiology tests. I had a PEG fitted, that's a feeding tube, in my stomach, and I thought, "Surely it's not going to be this bad." But that PEG, that feeding tube was a blessing in the end.  [00:07:40] Ali: And I had a mask made, and the mask fits you and basically pins you down to the radiotherapy table so you don't move when... because it's very precisely targeted at your tumour. So yeah, I went on to have five sessions of chemo, which felt quite easy. The radiotherapy was the really, really tough part. I had, uh, seven weeks of it, 35 sessions.  [00:08:08] Ali: So that was, yeah, that was a challenge.   [00:08:11] Florence: Thank you, Ali. Thank you for sharing that. I think it's always really valuable to get that patient perspective when we're talking about things like this. Lennard, I wanted to come back to you now to talk about the different types of vaccines that exist and which ones are being used specifically in the treatment of cancer.  [00:08:30] Lennard: Um, thanks, Florence. And Ali, are you 10 years now down the line since your diagnosis?   [00:08:34] Ali: Yeah, it feels good.   [00:08:37] Lennard: Congratulations.   [00:08:38] Ali: Yeah, yeah. It feels good. I really valued the follow-up checks that I had, both from my oncologist, but also I got some through the trial, and it really helped restore some confidence in myself and my body to deal with things and to be able to move on as well.  [00:08:56] Lennard: Oh, well done. That's fantastic because you telling us that story just really brings it to life about how scary this can be and also the fact that you had to go through all those sessions, thirty-five sessions and, um, and now you're 10 years down the line and still talking and giving hope-   [00:09:11] Ali: Yeah ...   [00:09:11] Lennard: that new technology still comes, so thanks, Ali.  [00:09:13] Ali: That's a pleasure.   [00:09:14] Lennard: Um, yeah, so Frances, this is what's really exciting. What types of vaccines are there? Well, first thing to say is that we're really good in this country about vaccine research. If you look around the world, what are we good at? Well, everyone knows that we developed the pandemic vaccine, and actually that technology is something that we can control.  [00:09:31] Lennard: We're world leaders at. It's quite cheap technology, and it's something that we are really good at bringing to patients. And Ali's our testament where she got on the trial, she helped test it and really pioneered new ways of research. So what types of vaccines are there? Well, I think we talked to the first bit where Victoria taught us that some of them can treat cancers and some of them can maybe prevent cancers.  [00:09:53] Lennard: And the HPV's one which is maybe be able to do both one day, which is brilliant. What would like... what else do people know about? Well, people might know that there are different types of technologies. So if we think back a few years now, back to 2020, there are some which are viral-based, and some which are mRNA based.  [00:10:12] Lennard: Both of these were new technologies which the whole population of the world came together to create and some of them are peptide-based. So there's probably three different types here. The protein ones or peptide one, which you always had, and then in the last five years, it's an incredible time to be alive, where new vaccine technology comes through, it's more effective and safer.  [00:10:32] Lennard: These are the viral ones and mRNA ones, and everyone's now pursuing all of these to try and make sure that we can maybe treat cancer in future.   [00:10:41] Florence: Can I possibly pick your brain a little bit more about the mRNA ones specifically? I think as you mentioned, lots of people might have heard of those during COVID.  [00:10:50] Florence: Could you maybe explain a little bit more about those and how they work?   [00:10:53] Lennard: Yeah. So this is going to take us all the way back to GCE biology now. If you remember - and we are Genomics England, so we, we got to work out why genomics is important, and we'll probably get to this. But remember, genes make RNA, which then makes protein.  [00:11:11] Lennard: And so if you're trying to reprogramme the immune response, you could give your body a protein, the back end of it. You can maybe give it an RNA, which is a blueprint too. And so what an mRNA vaccine is, it's a way of giving the blueprint or the instructions to the body of what to recognise, what the cancer looks like, um, um, or what the virus looks like, and target it.  [00:11:32] Lennard: If you want the analogy, well, for those people who had the pandemic vaccines, the ones which was mRNA based was, uh, the Pfizer one, and that worked really, really well. Cheap to make, easy to produce, and, uh, it's just a jab. And so people are now exploring that for cancer treatment now. Take new technology, which has only been developed five years ago, technology, which is just a blueprint, cheap to make, easy to update, and now we're targeting cancer.  [00:11:59] Lennard: Um, so that's basically what an mRNA vaccine is, giving the body the blueprint or the instruction of what a cancer looks like and trying to target that cancer.   [00:12:08] Florence: And you kind of alluded to it a little bit in your answer, but, um, it would be good to know more about where genomics comes into all of this. You know, why is it such an important part of developing vaccines?  [00:12:18] Lennard: And that's a great question, and really comes back to our second strengths, which is that we're really good at vaccine research, and yet we are also world leaders at genomic research. It's a really exciting time because, um, when Victoria and me and Ally at school, we would-- we, we learnt about that race to sequence the first human genome.  [00:12:38] Lennard: It was really exciting because for the first time, we can see every single genetic base in every human, and that used to cost billions of pounds to do that, and it would take many months or years to do that Fast-forward a few years, and then now Genomics England delivered the next success for humanity.  [00:12:57] Lennard: I think it was about 2015 to 2017 where they, they did 100,000 Genome Project, where the UK led the world in sequencing 100,000 people, including people with cancer, to try and understand what caused their cancer, what the risk factors are. And why is that relevant now? Well, it's because if you know what a cancer looks like, then you know what the abnormality is, well, then you can vaccinate against it.  [00:13:22] Lennard: So we've now gone from this amazing arc of discovery here, where when we were at school, we worked out what the human genome looks like. We can sequence it end to end and see in all its detail. Then a, an amazing organisation came out the ground called Genomic England, which shows that you can run it in the NHS.  [00:13:39] Lennard: 100,000 people could do it. And now we're making the next big jump now, which is it's not just going to give you a diagnosis, but maybe becomes a drug and a vaccine in future. And actually, probably it already has because Ali's that example, a success example of it happening.   [00:13:54] Florence: Yeah, I wanted to actually ask you about that, Ali.  [00:13:56] Florence: So just as you were saying, Lennard, it kind of... The cancer vaccine sounds quite futuristic, but as you said, it's, it's sort of already happening. So Ali, do you remember kind of how you first heard about the cancer vaccine trial?   [00:14:11] Ali: Yeah. I had a bit of an unfortunate time because after all that radio and chemo, my cancer still hadn't gone, and I had to have an operation to remove lymph nodes.  [00:14:22] Ali: But my oncologist at Poole Hospital, who's a fantastic woman, she had been involved, unknown to me, in the some of the thinking behind the trial, and particularly that she could recruit people because they were sat in her office. So she asked me if I'd like to take part, and without knowing anything, I said yes.  [00:14:49] Ali: And the reason I said yes was because my treatment really was punishing. It was so many side effects to it. The cancer never made me feel sick, but the treatment made me really sick. So I said yes because I just wanted to help other people not have to go through what I went through. I didn't really understand it, if I'm perfectly honest.  [00:15:16] Ali: I didn't really know what was going on, but then I'm not, you know, a super brain like Lennard and Victoria. I knew that I just wanted to do something to help people going forward, not having to deal with the same. So yeah, I put my hand up and there I was on the trial.   [00:15:37] Florence: So you mentioned there the, the really horrible side effects that you got from your original treatment. Did you have, um, what was your experience with side effects with the vaccine? Was it similar? Was it different?   [00:15:47] Ali: Oh, no, the, the vaccine was like a holiday compared to the treatment. Absolutely. At, at worst, in the first few treatments, you felt a bit like you had a cold, bad cold coming on, maybe slightly flu-y, but you took, you were given Ibuprofen at the same time as you had the vaccine.  [00:16:10] Ali: So no, it, the treatment with the vaccine was an absolute breeze. Which is kind of like, yes, this is what I want for people. You know, not, not the radiotherapy, not the chemo. So yeah, it was, it was really very easy by comparison.   [00:16:29] Florence: Oh, I'm so glad to hear that that was your experience. I'm just curious now also, was there anything that surprised you about the trial?  [00:16:35] Florence: You said there that you didn't really, like, have an understanding of cancer vaccines. You, you agreed to it straight away. Was there anything that maybe, like, you weren't expecting or surprised you?   [00:16:45] Ali: I think it surprised me that it was really quite easy.   [00:16:48] Florence: Yeah.   [00:16:49] Ali: Uh, I was delighted to have the team I had looking after me because they were fantastic. It all felt very simple.  [00:16:59] Ali: And how nice that was. You know, if I could've had that instead of all my previous treatments, um, it would've, it would've made everyone's life so much easier. And I guess, I don't know about the cost of drugs, but I guess the cost to the NHS would've been less because I wasn't in and out of hospital, I wasn't having to have all these extra things done, and all this extra support like dieticians and so on because I had to have my feed tube replaced.  [00:17:35] Ali: So all of that is impacts on the NHS, whereas this was very simple.   [00:17:40] Florence: I wanted to come to you now, Victoria, and ask you about the outcomes of this trial that Ali took part in or other trials like it, and whether we know yet what the broader implications of, of these advances might be.   [00:17:55] Victoria: So I think what we need to think about when we're thinking about developing these treatments and sort of evaluating the treatments at each stage is that it goes through a very clear pathway of progression, and Ali was involved in one of the, the earliest stages of that progression.  [00:18:09] Victoria: And it's, it's always amazing to me to hear your story, Ali, and to know that patients are willing to take part in the research and that's what allows us to develop these treatments. So the trial that Ali was part of has now gone on to develop into a, a larger scale study which will be evaluated again.  [00:18:27] Victoria: And that all starts to form the evidence for how these treatments can be shown to be effective, and also how they can show... Also, you know, Ali's already touched on there about the cost implications, so how we can show that that can be beneficial as well. And then we can start to think about how they can be taken up and become part of routine standard of care for patients like Ali, as she was describing.  [00:18:50] Victoria: And all of that evidence comes together, which then gets evaluated and then it, and then it moves forward through that progression. But it's-- we have very clear, um, you know, a, a route that each new, new treatment has to go through, um, to be able to, to become part of standard of care.   [00:19:07] Florence: And Victoria, you also play a key role in the Cancer Vaccine Launchpad.  [00:19:12] Florence: For any listeners who might not be familiar with the Cancer Vaccine Launchpad, could you maybe tell us a little bit more about it?   [00:19:18] Victoria: Absolutely. So in its simplest terms, the Cancer Vaccine Launchpad is designed to help find patients who might be eligible to take part in trials like the one that Ali was part of.  [00:19:30] Victoria: It's an incredible project. Cancer Vaccine Launchpad is quite long, so we tend to abbreviate it to the CVLP, which I'll do from now on, if that's okay. The CVLP to me really demonstrates the power of collaboration because it's brought together so many different teams that have been necessary to make sure that, that what we're trying to achieve, so finding as many patients as possible for these trials, is possible.  [00:19:52] Victoria: We deliver this project on behalf of NHS England. I know that Lennard was involved right from the start as well. The reason that we need the CVLP is because one of the biggest challenges in research of these new treatments is finding the patients who might be eligible. So one of the reasons for that is because when we are running the trials to test these new treatments, there's a lot of different infrastructure that's needed to support the delivery of those trials.  [00:20:19] Victoria: So you need special pharmacy services, special research nurses. All of that has to come together to be able to deliver trials of new treatments. And actually, that means that actually those studies can often only take part in a small number of hospitals. So historically, you only had the opportunity to take part in those trials if you lived near one of those hospitals, which is, you know, like Ali did.  [00:20:42] Victoria: So what the CVLP is, what, what it has done, it has created a formalised network which enables referrals to happen from ... we're opening 83 hospitals now across England. We've just expanded out to the devolved nations as well, which is a really exciting development, and it creates that, that network which allows patients who might live further away from a hospital delivering one of those vaccine or immunology trials to be able to be referred in to see if they might be eligible.  [00:21:09] Victoria: So essentially, it's a bit like creating a big funnel. So you're finding all of the potentially eligible people that could take part in that trial, and you're funnelling them into the trial site to find those patients who are eligible.   [00:21:22] Florence: And what impact do you hope that this could have for the NHS and also for, like, individual patients as well?  [00:21:29] Victoria: So we've seen such positive results from the CVLP so far. The first study that we worked with was for a colorectal cancer vaccine trial. Before the CVLP started working with this trial, only 17% of the eligible patient population in England had the opportunity to take part because they lived near one of those hospitals delivering the trial.  [00:21:52] Victoria: After the CVLP started working with it, we had increased that to over 60% of the eligible patient population. So you could really see how it has expanded out access, and that's just a fantastic opportunity to be able to bring, to bring patients. We also were able to show that the UK was screening, so looking for patients at three times the global average.  [00:22:14] Victoria: So we really were able to see how the CVLP is supporting and accelerating recruitment to those trials I think the key thing for me has been the patient enthusiasm that we have seen though. So when we open up to a new trial where, that the CVRP is working with, we are always inundated with people who contact us to find out how they can be part of this network because they want the opportunity to take part.  [00:22:40] Victoria: We know that some patients have travelled for two hours to a trial site to find out if they could be eligible because actually they want the opportunity. So the CVRP has really sort of enabled that patient choice, which is a fantastic thing to be able to do. But it also builds on what Lennard was talking about earlier, which is the UK is really good at this research and actually what the CVRP is then doing is showing how we can really support recruitment to these trials to accelerate these trials and that only brings more trials to the UK which again creates more opportunities for patients which is exactly what we're trying to do.  [00:23:14] Victoria: We're trying to create more and more opportunities for patients to take part in these studies if they want to.   [00:23:20] Florence: Yeah. That's really incredible. Thank you for sharing that with us. I wanted to ask you a question now, Ali, because I think when we were talking about trials and projects like this, as Victoria said, we often think about kind of the high level impact, but also it's an opportunity to create connections as well between patients and families and, and I know that you, you had a patient's family reach out to you about advice as to-- about whether they should take part in a trial. Is that right?   [00:23:47] Ali: Yeah. I think it was the wife of a guy up in Liverpool who had throat cancer, and, um, she must have done some really good research on the internet. I'd done various bits of publicity both for Southampton Uni and cancer research around the trial. So she obviously found me and then stalked me on Facebook , which was absolutely fine.  [00:24:13] Ali: I didn't have a problem. So her husband was down to go on the trial, which is the next stage that Victoria had spoken about, and she just wanted to know, would I recommend it, would-- what was it like, that kind of thing. So I said to her, "I would absolutely recommend it, of course," and told her what my experience was.  [00:24:35] Ali: I couldn't guarantee his would be the same, of course, because things might have moved on. But it was a really, it was a kind of a nice feeling that I could say to her, "Get him to have it done because it's got to be the best outcome." I think his stage was much further on than me. So yeah, it had to be the way as far as I could see for him. And as far as I know, he went on the trial. Which is great.   [00:25:05] Florence: How, how did it feel to kind of make that human connection, maybe not something you were expecting to come out of a trial?   [00:25:13] Ali: No, it was really, it was really nice. I am a bit of a, a fangirl for, for Lennard and Victoria and all the team at Southampton.  [00:25:22] Ali: If anybody asks me about vaccines and cancer vaccines, I'm like, "Oh, yes." And you-- So yeah, I'm, I'm a bit of an evangelist. So to, to have somebody real-   [00:25:33] Florence: Mm ...   [00:25:34] Ali: ask me about that was great feeling.   [00:25:37] Florence: I think that's a, a really great example of how research can have impact far beyond, uh, one individual. And I think another great example of this is also artificial intelligence or AI as a potentially transformative force in, in healthcare.  [00:25:54] Florence: Lennard, when we come onto this topic, I wanted to hand over to you because I know that you've recently received funding for a project exploring AI, and how it could support cancer vaccine development in particular. Could you tell us a bit more about this project?   [00:26:08] Lennard: Thanks very much, Florence. And I also want to add, I feel very proud about what Ali did just there, where she's able to bring through opportunity for other people, too, which is amazing.  [00:26:19] Lennard: The NHS is there to not just do the technology of today, but also be one of the best healthcare systems in the world to bring through new technologies. And it's just really exciting about people wanting to help the NHS, advocating for new technologies to be tested, and actually that's what Genomics England i there to do, make sure the NHS gets new technology in there so that patients will get new treatments.  [00:26:41] Lennard: I just wanna just reflect what Victoria noted In the NHS, in their Cancer Vaccine Launchpad, patients are getting in at three times the rate of other countries.   [00:26:51] Ali: Mm-hmm.   [00:26:52] Lennard: That's really special. And also she's increased coverage to, uh, did you say 60% of population? That's 42 million people have potential access to this.  [00:27:01] Lennard: So that is huge, and I think it's really a passion project for so many people out there, PICT trials units, the research nurses and doctors, and also patients who make this all happen. So it is quite impressive. It is very impressive. Oh, yes, and AI. I probably should cover that too. Just beyond what's special about the NHS and Genomics England.  [00:27:22] Lennard: Well, AI I think is changing everything. I went to a garden party, and actually everyone's talking about how they're using AI to make their lives simpler, make them do things that they've never been able to do before, get the information instantaneously there. And I think that there's technologies which come through every so often in our lifetimes, which changes how we think, how we communicate, and actually makes us better in many ways.  [00:27:47] Lennard: And so the great opportunity here is what happens if we take that third strength now? So we've already said we're really good at vaccine research in the UK. The UK invented vaccines. We also are world leaders at genomics. We did the 100,000 Genome Project. What happens if we use this new technology now?  [00:28:06] Lennard: And what's a problem that we can solve? Well, let's say we did a whole genome sequence on someone, which is what Genomics England does every day for the NHS. Well, that creates a lot of data. Um, I tried to do the calculations before we went online. It's about 100,000 photos. You know, when you take on your phone, that's a lot of data.  [00:28:25] Florence: Wow. Yeah.   [00:28:26] Lennard: And that's a miracle what's happening in the NHS and Genomic England, and we need to make a cancer vaccine out of that. And so you need to process that. So that's time-consuming. It could be automated. And so what AI could do now in future is that we could use the supercomputer we built in the UK.  [00:28:43] Lennard: In fact, we are doing this already. We've built supercomputers in the UK, and we're going well beyond other tools out there and designing cancer vaccines. And the AI scientists which can do that can do it at weekends, at nights, and help design the drugs. And so what it does is it heralds a future where every patient can contribute into a model that's created in the UK, stored safely in our supercomputers.  [00:29:07] Lennard: It can now be made into drugs, and the UK will start to make things again, which will hopefully change cancer care across the world. We can deliver that legacy whereby our three strongest strengths come together - vaccines, AI, and genomics. It then super powers the NHS and everything that Victoria's done in the Cancer Vaccine Launchpad, so many millions of people around the world can get access to trials.  [00:29:31] Lennard: And people like Ali can also help hold up the NHS even further. So people once again look back to us and say, "If you want to get things done, come to the NHS because it provides world-class care for patients." And so that's a big initiative now. Use AI to make better drugs, safer drugs, more effective, more precise in the UK. And it's only possible because of everything that we've built here with our funders, ARIA, MRC, Cancer Research UK, people raising, raising money through cake bake sales to make this happen.  [00:30:02] Lennard: So it's very exciting.   [00:30:04] Florence: Yeah. I think AI can be a topic that people often have very strong opinions about. When it comes to AI in, in your line of work, are there any misconceptions you think people might have, or are there any benefits to using it that maybe people might not be aware of?   [00:30:21] Lennard: Oh, that's a tricky question, isn't it? I think you're right. Any tool that comes through can be used for good things and, and things that people will question because maybe we don't want to cross those boundaries. And yet I think what we're doing here is really special because we want to - as long as your heart's in the right place - we want to give more people like Ali hope so that she knows that one day the drugs in the NHS will be much safer so you don't get all those side effects, much more effective, much more precise.  [00:30:52] Lennard: And on top of that, people like Victoria will be able to bring even more trials in the UK which will change lives and change practices around the world through an amazing working launchpad. So I think that's the right use of AI, make people's lives better. I think there are other uses of AI which I probably scratch my head and say, "Well, should we be doing that?"  [00:31:10] Lennard: And that's what I think it's really special that we do think about these and talk about these things here, and then bring the public with us because I know that people reach out, and Ali's been reached out in the past before, and I think we need to have this discussion here. Is AI right to develop cancer drugs using capabilities from Genomic England to go through the NHS Cancer Vaccine Launchpad?  [00:31:31] Lennard: I say cautiously, yes, and we should do more of this. And I think the most important thing is there's a lot of people starting to use AI for benefit, and you know my views, Ali, and I don't know if they're right. Um, I'll be a bit cautious, but I do want to ask you, Ali, is this the right use of AI? Should this be what we develop?  [00:31:50] Lennard: I don't know what you're going to say.   [00:31:52] Ali: For me, I think it is. I do think AI is a bit if you put rubbish in, you get rubbish out. But if you- If you ask the right questions, if you give it data analysis and experts like you have set up the protocol in the first place and it makes everything faster and reliable, then it's got to be the right thing.  [00:32:16] Ali: It gets used and abused for things, that isn't what AI should be doing, in my opinion. It should be used to do-- to help us, to supplement the work that we're doing, uh, and make it even faster than you're already making it.  [00:32:38] Florence: Well, we've covered so much today from how vaccines work to the role of genomics, NHS trials, and of course, what all of this could lead to. So before we wrap up, I have two final questions for each of you. What do you think is the most important thing for listeners to understand and take away from personalised cancer vaccines?  [00:33:01] Florence: And what are your hopes for the future? I think we'll start with you, Victoria, if that's all right.   [00:33:08] Victoria: Yeah, absolutely. It's been a great conversation. Uh, there's so much to think about. I think when I think about what I'd like listeners to take away, I think it's that cancer vaccines, and particularly personalised cancer vaccines, really support and represent this paradigm shift that we're seeing towards a much more personalised, uh, treatment pathway.  [00:33:27] Victoria: You know, like we've described, generating a cancer vaccine that has come from the patient's tumour, so the, the, the vaccine is, is designed to recognise mutations that are specific to that patient. It is such an incredible thing to be sort of witnessing and to see how that's developing through into sort of really changing patient care, and that's, you know, we've spoken about this so much, but that's been due to such incredible collaboration across scientific disciplines, across the NHS, pathologists.  [00:33:58] Victoria: Everyone has come together to make all of this possible, and that's, that's an amazing thing to be a part of. In terms of my hopes for the future, well, I would like the Cancer Vaccine Launchpad to be open in every hospital across the UK to really sort of underpin that acceleration and to provide that opportunity for patients.  [00:34:17] Victoria: You know, I'd just like to give a, a final shout-out to everybody who has been part of the Cancer Vaccine Launchpad from its very start, who's enabled this to happen and, you know, it's just been fantastic to see how this has, you know, supported patient choice for trials. And I guess if there's one tiny other thing, perhaps we could see how this, you know, this, what we've put together could be applied to other disease areas as well.  [00:34:39] Victoria: But yeah, that, that would be my hope for the future, is it's open everywhere one day.   [00:34:43] Florence: And Ali, I'll come over to you next.   [00:34:45] Ali: I think what I'd say to any patient that was asked to go on a trial is, is just go for it.  [00:35:02] Ali: And you know, Victoria, Lennard, all the rest of the team, you know, you are not doing jobs. You're leaving a legacy in my view. That's such an important thing. So yeah, if you're offered a trial, get on it. And my hope for the future is that everybody can have kinder, gentler treatments. The radiologists and chemo nurses I came across were lovely, lovely people.  [00:35:31] Ali: But yes, I'd like to see them out of work and doing other things within the NHS because they don't need to do that work anymore. That, that's my dream.   [00:35:40] Florence: Mm. And Lennard, any, any final thoughts?   [00:35:44] Lennard: Thanks, Ali. I mean, your words gave me goosebumps about the amazing stuff that the whole community's doing for cancer vaccines, AI and genomic research.  [00:35:51] Lennard: It's so powerful. Um, okay. What's the final thing? I think it's hope. Look, the country's in a new place now. You've got brilliant scientists running clinical trials, like the Cancer Vaccine Launchpad, which is reaching out to every single hospital. You've got patients who are building up the NHS again to deliver future care, and scientists using AI and genomics to make cancer vaccines.  [00:36:11] Lennard: That is a good reason to be hopeful. When lots of things are going in other places of the world, great things are happening in the UK.   [00:36:20] Florence: This has been such a brilliant conversation.  [00:36:25] Florence: A huge, huge thank you to our guests today, Dr. Victoria Goss, Professor Lennard Lee, and Ali Richards, for joining me in our brilliant discussion about cancer vaccines.   [00:36:50] Victoria: Thank you so much for having me.  [00:36:55] Ali: Thank you, as always. I've learnt a lot.   [00:37:00] Lennard: Thank you very much, Florence, too, from me.   [00:37:10] Florence: If listeners have enjoyed this episode and you'd like to hear more, please subscribe to Behind the Genes on your favourite podcast app.  [00:37:16] Florence: I've been your host, Florence Cornish, and Behind the Genes is produced by Deanna Barac, Sharon Jones, Sophie McLachlan, and Patrick Wallace at Bespoken Media. Thank you for listening.   

Guests Include: Dr. Duke Show's Duke Pesta, MRC's Tim Graham, Attorney Mike Pugliese, Department of Education's David Barker, Wisconsin Right Now's Jessica McBride, Former State Rep. Janel Brandtjen

MRC handles the middle of February 1969 with Fantastic Four 83, Captain Marvel 10, Sub-Mariner 10, Silver Surfer 4, and Nick Fury Agent of SHIELD 9. It's a totally different story if you replace the Atmo-Gun with the Hypno-Gun! Check it out!

Guests Include: RPW Chair Brian Schimming, Former State Rep. Janel Brandtjen, MRC's Tim Graham, CFACT's Chris Martz, Wisconsin Right Now's Jessica McBride, Former Governor Scott Walker

MRC launches into February 1969 with Amazing Spider-Man 69, Daredevil 49, Thor 161, X-Men 53, and Incredible Hulk 112, featuring the entirely underwhelming debut of Barry (Not Yet Windsor) Smith!

Rev. Lee F. Veazey visits MRC and opens God's Word to the great 23rd Psalm. Psalm 23 has the undisputed place of being the most well-known and well-loved Psalm, the most famous and most familiar of all 150 chapters in the Psalms.  This is not without good reason, for the six verses of Psalm 23 are full of confidence and trust in the Lord.  Indeed, Psalm 23 has been on the lips of the very young as they are learning to speak and on the lips of the dying as they are taking their last breaths.  The center and anchor of the psalm is the declaration that “you are with me” (v. 4).  Here's Psalm 23 on the back of a t-shirt:  “No lack.  No fear.  No end.” 

CNN reporter Donie O'Sullivan hosted a Sunday night special tilted "The Left Insurgency," promoting radical leftist Hasan Piker's designs on the Democratic Party. When Jorge Bonilla began tweeting video during the show, Donie started mocking Jorge and the MRC on X. 

Guests Include: Dr. Duke Show's Duke Pesta, Badger Institute's Pat McIlheran, MRC's Curtis Houck FAIR's Ira Melman, RPW Chair Brian Schimming, Rep Bryan Steil

MRC finishes up January 1969 with Nick Fury Agent of SHIELD 8, Doctor Strange 176, Iron Man 9, Captain America 109, and Avengers 60! The desperate need for new marriage laws in New York State, panel borders gone berserk, and lots of other crises! Check it out!

Guests Include: Landmark Legal's Michael O'Neill, Save our States' Trent England, MRC's Tim Graham, Dr. Duke Show's Duke Pesta, WILL's Dan Lennington

Hey, where's Star Lord?? MRC covers part 2 of January, 1969, introducing the (original) Guardians of the Galaxy in Marvel Super-Heroes 18, plus Fantastic Four 82, Captain Marvel 9 and Sub-Mariner 9! Check it out!

David Bozell discusses his family's conservative political background in Washington, D.C., and how his father helped launch the Media Research Center after earlier work with NCPAC. He describes the MRC's early years as resource-poor but focused on documenting media bias, including work at the 1988 conventions and support from donors and figures in conservative media. He also talks about the organization's relationship with Rush Limbaugh, saying MRC supplied clips and documentation that supported Limbaugh's on-air commentary. Bozell reflects on Limbaugh's influence and on how conservative media grew through talk radio and strong messaging. Bozell then explains how MRC's focus has shifted to digital platforms such as Apple News, Google News, Yahoo, and MSN, where he says the organization tracks the visibility of center-right voices. He closes by urging audiences to share content, contact news platforms about imbalance, and push for more conservative sources in mainstream distribution.   Connect with David

Season 8, Episode 5: How did Madison Realty Capital grow from a $10M fund into one of the most active private credit platforms in real estate? Today, we sit down with Josh Zegen, Co-Founder and Managing Principal of Madison Realty Capital, to break down how MRC built its lending business before private credit became an institutional asset class. Josh shares how the firm survived the GFC, became vertically integrated, and scaled into a major capital source for sponsors when banks pulled back. Whether you're interested in distressed debt, construction lending, office-to-residential conversions, or today's maturity wall, this episode is a must-listen. Join us as we dive into how Madison thinks about risk, rescue capital, borrower relationships, and finding opportunity in a volatile market. Shoutout to our sponsor, Lennar Investor Marketplace. New construction rental investments with comps, returns, and underwriting built in. TOPICS 00:00 – Introduction to Josh Zegen and Madison Realty Capital 05:00 – The Early Private Credit Opportunity 10:53 – Surviving the GFC and Taking Over Assets 15:45 – Becoming a Construction Lending Powerhouse 19:00 – Back Leverage and Lending to Lenders 24:12 – Distress, Rescue Capital, and Loan Workouts 31:24 – Fundraising, Insurance Capital, and Investor Demand 35:44 – The Pfizer Office-to-Residential Conversion 42:40 – West Palm Beach, Florida, Texas, and Hot Markets 48:12 – Recaps, Volatility, and Building Through the Cycle For more episodes of No Cap by CRE Daily visit https://www.credaily.com/podcast/ Watch this episode on YouTube: https://www.youtube.com/@NoCapCREDaily About No Cap Podcast Commercial real estate is a $20 trillion industry and a force that shapes America's economic fabric and culture. No Cap by CRE Daily is the commercial real estate podcast that gives you an unfiltered ”No Cap” look into the industry's biggest trends and the money game behind them. Each week co-hosts Jack Stone and Alex Gornik break down the latest headlines with some of the most influential and entertaining figures in commercial real estate. About CRE Daily  CRE Daily is a digital media company covering the business of commercial real estate. Our mission is to empower professionals with the knowledge they need to make smarter decisions and do more business. We do this through our flagship newsletter (CRE Daily) which is read by 65,000+ investors, developers, brokers, and business leaders across the country. Our smart brevity format combined with need-to-know trends has made us one of the fastest growing media brands in commercial real estate.

- Mike, Susie, and Jerome respond to the MRC's "Worst of the Week" clips- Mike brings you the hard hitting stories that mainstream media is too chicken to air... including a kitten used to try robbing a bank. - Jennifer Oliver O'Connell joins to talk about election integrity See omnystudio.com/listener for privacy information.

Is the AI industry actually overbuilding, or is the physical world moving too slowly to keep up? In this episode of the MAD Podcast, OpenAI's Head of Industrial Compute, Sachin Katti, takes us inside the "belly of the beast" of what may be the largest infrastructure project in human history. We explore the staggering physical reality of the AI boom—from $50 billion supercomputers and liquid-cooled data centers that "turn electrons into tokens," to overhauling the U.S. power grid and exploring nuclear energy. Sachin also pulls back the curtain on OpenAI's Stargate strategy, their move into custom silicon with Project Jalapeno, and the mind-bending reality that AI is now beginning to design the very chips that will power its own future.(00:00) — Cold open: “One of the largest things humanity has ever built”(00:30) — Welcome: Sachin Katti, Head of Industrial Compute at OpenAI(01:44) — Is this the biggest infrastructure buildout in history?(03:41) — Why OpenAI is building a new industrial muscle(04:54) — What an AI data center actually is(05:27) — “Factories turning electrons into tokens”(06:35) — Why AI data centers need liquid cooling everywhere(08:10) — The power problem: grids, generation, transmission, substations(10:43) — Behind-the-meter power and gas turbines(11:02) — Why nuclear “can't come soon enough”(11:49) — Jalapeño: why OpenAI is designing its own AI chips(13:19) — Tokens per watt: the new metric that matters(13:38) — Why inference may now dominate AI compute(14:58) — Is OpenAI overbuilding compute?(16:47) — Why OpenAI thinks the bigger risk is not building fast enough(17:55) — Communities, jobs, water, and the local data-center debate(21:16) — How OpenAI chooses data-center sites(22:25) — What “industrial compute” means inside OpenAI(25:59) — Sachin's path: Stanford, startups, Intel, OpenAI(28:05) — OpenAI's compute portfolio: Microsoft, hyperscalers, neoclouds(29:37) — Stargate explained(31:21) — Abilene, Oracle, and the next wave of AI data centers(32:48) — How massive AI compute gets financed(34:05) — How OpenAI designed Jalapeño so quickly(35:59) — AI is starting to help design AI chips(36:20) — MRC: the networking problem behind 100,000 GPUs(38:47) — Bottlenecks: transformers, turbines, electricians, supply chains(40:29) — Guaranteed capacity: intelligence as a supply unit(42:08) — Will AI data centers move to space?

UV filters are one of those deceptively simple pieces of camera gear that somehow manage to spark wildly passionate opinions.Some photographers swear by them. Others won't let them anywhere near their expensive glass. And somewhere in the middle are a whole lot of people wondering, “Wait… do I actually need one of these things?”In this episode of The Wild Photographer, we're taking a practical, field-tested look at UV filters: what they are, why they exist, why they mattered more in the film era, and why many photographers still use them today even though digital cameras don't really need UV filtration in the same way.The big shift is this: for most modern photographers, UV filters are no longer about filtering UV light. They're about protection.A good UV filter acts like a clear, protective layer in front of your lens. It can help shield your front element from scratches, smudges, dust, rain, mud, salt spray, and the occasional “oops, that branch was closer than I thought” moment. And for photographers who travel, guide, shoot in rough conditions, or frequently clean their gear in the field, that extra layer can provide a lot of peace of mind.But there are trade-offs. Cheap filters can potentially degrade image quality, stacking filters can cause issues like vignetting or optical weirdness, and if you're using extremely high-end prime lenses, there's a very reasonable argument that you may not want to place a lower-quality piece of glass in front of a truly elite lens.So this episode is less about declaring UV filters “good” or “bad,” and more about understanding when they make sense, when they don't, and how to shop for one if you decide to use them.UV Filter Product Links MentionedHere are the UV filter brands and shopping resources mentioned in the episode:PolarPro QuartzLine UV Filters — a higher-end UV filter option with quartz glass, anti-reflection coatings, scratch protection, and no exposure adjustment needed.Hoya UV Filters at B&H Photo — Hoya offers a wide range of UV and protective filters, including multi-coated and higher-end HD options.Hoya HD3 UV Filter — a premium Hoya UV filter with nano multicoating, scratch resistance, water and oil repellency, and no exposure change.B+W UV-Haze MRC MASTER Filter — a high-quality UV protection filter with MRC nano coating and low reflective qualities.B+W Clear Protection Filter — a clear protective filter option designed to protect against dust, fingerprints, splashing water, and other field hazards.B&H Photo Protective and UV Filters — a useful place to compare UV, haze, and protective filters by size, brand, price, and coating type.Lensrentals — a place where photographers can research or rent gear, including filters depending on availability.Final TakeawayUV filters are not magic. They will not transform your photos, make your colors explode, or really much of anything when it comes to look.But a good UV filter can protect your lens, make cleaning easier, reduce stress in rugged field conditions, and help preserve resale value. For most lenses, especially everyday travel, wildlife, and landscape lenses, I think they're a very smart investment.The key is to buy a good one. Look for reputable brands, multi-coated glass, and a price point that matches the quality of the lens you're protecting.And when you're stacking filters, working with ultra-premium glass, or chasing the absolute highest optical quality possible, that may be the time to take the UV filter off and let the lens do its thing.Court's WebsitesCheck out my photo portfolio here: shop.courtwhelan.comSign up for my photo and conservation blog at www.courtwhelan.comFollow me on YouTube (@courtwhelan) for more photography tipsView my camera kit and recommended camera gearSponsors and Promo Codes:MPB.com - Buy, Sell, or Trade Camera GearArtStorefronts.com - Mention this podcast for free photo website designBayPhoto.com - 25% off your first order (code: TWP25) ArtHelper.com - a photo community to learn, share and be inspiredArthelper.Ai - Smart tools to promo and showcase your art.LensRentals.com - WildPhoto15 for 15% off

MRC pickets January of 1969 with Amazing Spider-Man 68, Daredevil 48, Thor 160, X-Men 52, and Incredible Hulk 111! The year of the moon landing and Woodstock has finally arrived! Groovy!

- Amsterdam-style cannabis cafes in San Francisco. Should we consider allowing them here?- MRC's Worst of the Week - Stacey Matthew has some thoughts on Zoran Mamdani thinking he's an international diplomat,See omnystudio.com/listener for privacy information.

Guests Include: Film Director Michael Pack, Junk Science's Steve Miloy, MRC's Tim Graham, Conservative Caucus' Jim Pfaff, Dairyland Sentinel's Brian Fraley, Heritage Foundation's Corey D'Angelis

Guests Include: Junk Science's Steve Milloy, Advancing American Freedom's Amy Swearer, MRC's Tim Graham, Americans for Tax Reform's Grover Norquist, The Federalist's Matt Kittle, Senator Ron Johnson

MRC finally does away with 1968! To finish up December, we've got Nick Fury Agent of SHIELD 7, Doctor Strange 175, Iron Man 8, Captain America 108, and Avengers 59! Springer approaches Steranko territory! The Trapster finds out he has a jar of Elmer's paste! Hank Pym somehow gets even worse! Check it out!

Greg Roberts from Rogue Weather Dot Com has the latest Outdoor Report, Bob Haworth performs Saturday in Shady Cove, He tells us more, THE MRC did research on the AI Chatbots...do they lie about the founding of the country? (Yep)

Join FPC Executive Director and CEO Reed Luhtanen as he goes off the rails with Keith Briscoe, VP Member Advocacy at the Merchant Risk Council. Keith and Reed talk about MRC's recent payments and fraud trends report, AI, faster payments for retail, and orchids. Connect with Reed at MRC San Diego September 14-16!Follow FPC on Linkedin! https://www.linkedin.com/company/us-faster-payments-council/posts/?feedView=all

Guests Include: FAIR's Hannah Davis, MacIver Institute's Annette Olson, Heartland Institute's James Taylor, MRC's Tim Graham, Rep.Derrick Van Orden, WILL's Rebecca Furdek

MRC soldiers on through December 1968 with Fantastic Four 81, Captain Marvel 8, Sub-Mariner 8, and Silver Surfer 3! More wonder-gloves! More evidence that maybe Colletta on Heck wasn't such a good idea after all! Check it out!

Guests Include: Conservative Caucus Jim Pfaff, Dr. Duke Show's Duke Pesta, Crime Prevention Research Center's' John Lott, MRC's Tim Graham, Senator Ron Johnson, Moms for Liberty's Scarlett Johnson

MRC jumps into December 1968 with Amazing Spider-Man 67, Daredevil 47, Thor 159, X-Men 51, and Incredible Hulk 110! How is Daredevil better than the Steranko book?? Listen to find out!

This week, two debut authors received the Women's Prize for Fiction and Non-Fiction, each worth £30,000, respectively. Anita Rani spoke to the two winners, novelist Virginia Evans and Lyse Doucet, known to listeners as the BBC's Chief International Correspondent.The Women's T20 Cricket World Cup has begun. Nuala McGovern talked to Clare Connor, former England women's captain, now the outgoing Managing Director of England Women. Over her 18 years in the job, Clare has overseen the professionalisation of the women's game as well as a big boost in grassroots participation.The government has announced how it is planning to roll out quicker and easier access to educational psychologists, speech and language therapists, and occupational therapists for SEND families. Nuala spoke to the Schools Minister Georgia Gould and Principal Educational Psychologist for Salford, Claire Jackson, about the upcoming Experts at Hand programme.Last week, Hannah Murray, who played Gilly in Game of Thrones, told Anita that during the final season of the show, the papers wrote she was pregnant - when she wasn't. Hannah said that maybe this was the only acceptable way for a woman in the public eye to gain weight. Following a strong listener response, we discussed if there is a right way to talk about women's weight. Anita was joined by Alex Light, a body confidence activist and author and Dr Dolly Van Tulleken, food policy researcher, policy consultant and visiting researcher at the MRC epidemiologist unit in Cambridge University.Have you ever had one of those moments when life feels so circular that you just can't believe it? A 'once-in-a-lifetime synchronicity' is what the poet Emily Cullen called it when she discovered that a poem she had written seven years ago, inspired by her eight year old son, turned up on the English exam paper he was sitting in Ireland. Anita caught up with Emily and son Lee.Presenter: Anita Rani Producer: Annette Wells

Last night, two debut authors received the Women's Prize for Fiction and Non-Fiction, each worth £30,000, respectively. Anita Rani speaks to the two winners, novelist Virginia Evans and Lyse Doucet, known to listeners as the BBC's Chief International Correspondent.Last week, Hannah Murray, who played Gilly in Game of Thrones, told Anita that during the final season of the show, the papers wrote she was pregnant - when she wasn't. Hannah said that maybe this was the only acceptable way for a woman in the public eye to gain weight. Following a strong listener response to that item we discuss if there is a right way to talk about women's weight. Anita is joined by Alex Light, a body confidence activist and author and Dr Dolly Van Tulleken, food policy researcher, policy consultant and visiting researcher at the MRC epidemiologist unit in Cambridge University. England is hosting the 2026 T20 Women's World Cup this summer, and England and Sri Lanka launch the competition with their match at Edgbaston today. This is the first time that 12 teams will competing for the World Cup trophy – an increase on previous years. Anita talks to Melissa Story, a cricket player for Gloucestershire and a commentator for BBC's Test Match Special, about how the tournament works, the players to watch - and the matches we can't miss.This week the Royal College of Psychiatrists launched its first ever Women's Mental Health Strategy. It was instigated by Dr Lade Smith, president of the Royal College of Psychiatrists who chose women's mental health as a key focus when she took up her post three years ago. As Lade steps down from that role, she joins Anita to talk about why she thinks that the women's mental healthcare is in crisis and her vision for improvements.When bride-to-be Kayley Stead was left alone at the altar on her wedding day in 2022, she did what few would think to do - she let the wedding continue. Kayley's photos of enjoying her wedding alone, including the speeches, the first dance and cutting the cake, went viral. Other women congratulated her for celebrating herself and still enjoying the day. Four years on, she's found love again - she's engaged! - and she says she wants her wedding to be "a big party." She joins Anita. Presenter: Anita Rani Producer: Rebecca Myatt

Modern medicine's success in extending lifespans comes at an environmental cost. This lecture explores the pollution from single-use plastics, pharmaceuticals and medical waste, questioning whether we can sustain this model. It examines the impact of drugs and their metabolites on ecosystems, the carbon footprint of healthcare and the ethical dilemma of balancing individual health with planetary health. This talk explores potential solutions, including green pharmacy, innovative materials and responsible waste management, asking if a future with both healthy aging and a thriving planet is achievable.This lecture was recorded by Ian Mudway on the 12th of May 2026 at Bernard's Inn Hall, LondonDr Ian Mudway is Visiting Professor of Environmental Health. He is a senior lecturer in the School of Public Health at Imperial, a member of the MRC Centre for Environment and Health; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma and the NIHR-PHE Health Protection Research Units in Environmental Exposures and Health and Chemical and Radiation Threats and Hazards.He has over 25 years of experience researching the impacts of air pollution on human health and in the development of assays to quantify the toxicity of the chemical cocktails that pollute the air we breathe. Over this period Dr Mudway has published over 100 research papers, reports and book chapters on these topics, as well as providing advice to the local, national and international governments and NGOs. Dr Mudway is passionate about the communication of science to lay audiences and has worked extensively with artists and educationalist to promote the public understanding of the risks associated with environmental pollutants. Currently his work is focused on understanding early life impacts of pollutants on the development of the lung and cognitive function in children living within urban populations, as well as  furthering our fundamental understanding of the mechanisms that drive these adverse effects and modify an individual's susceptibility to air pollutionThe transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/pill-planetGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Hi there! Feel free to drop us a text if you enjoy the episode.In this episode of the New England Endurance Podcast, we head to Manchester, Connecticut, to sit down with David Fusfeld, President of the Manchester Running Club.David shares his own “adult onset runner” story, starting in his 30s, getting hooked on the marathon, qualifying for Boston, completing 23 marathons, and recently earning his Abbott World Marathon Majors Six Star medal. From there, we dive into the history and growth of Manchester Running Club, which started in 2009 and has become one of Connecticut's most active and visible running communities. The conversation explores how MRC balances competitive racing with a welcoming social culture, why group runs often work best when they mix workouts, breweries, long runs, and coffee, and what makes Manchester such a strong running town. David also highlights the club's signature events, including the Spring Street Mile & 5K and the MRC Track & Field Series, a summer event that brings hundreds of kids and adults to the track each week and helps introduce young athletes to the sport. We also talk about the broader Connecticut running scene, the growth of clubs across the state, the iconic Manchester Road Race on Thanksgiving, and why David believes Connecticut is “punching above its weight” as a running community.Whether you're a competitive runner, a social runner, a parent looking to get your kids involved, or someone nervous about joining a club for the first time, this episode is a great reminder that running is better when you find your people.Learn more:Manchester Running Club: manchesterrunningclub.comMRC Track & Field Series: mrctf.orgInstagram: @manchesterrunningclubPhotography: @meteredexposureThis podcast embarks on a journey to showcase and celebrate the endurance sports community in New England.

Guests Include: Institute for Reforming Government's Quinton Klabon, MRC's Luis Corneilio, Author Dr. Gilda Carle, Freedom Enterprise Project's Steve Milloy, Conservative Caucus' Jim Pfaff, WMC's Scott Manley

MRC wraps up the main books of November 1968 with Nick Fury Agent of SHIELD 6, Doctor Strange 174, Iron Man 7, Captain America 107, and Avengers 58. A Post-Steranko World! Satan-ish! Pym suckage will somehow only increase! Check it out!

Quality, Consequences and the Construction Industrial Complex (part 467)Our guest this episode is Ian Rudolph talking about regenerative design, training and qualifying as an Architect, insurance and much more.If you enjoy this episode, share it with friends and give us a review, it helps more than you know.In this episode, we discuss:De-construction materials as waste in the wrong spaceDe-construction rather than demolition60% of UK waste generated by constructionActual regenerative projectsAnd much more…….More on IanIan on LinkedIn: https://www.linkedin.com/in/ian-rudolph-9396a512/Marks Barfield Architects: https://marksbarfield.com/Marks Barfield Architects Circular Economy Explainer: https://marksbarfield.com/projects/beyondsustainability/22 Baker Street case study: https://marksbarfield.com/projects/22-baker-street/Oasis Nature Building Case Study: https://marksbarfield.com/oasis-nature-building/The Lantern Case Study: https://marksbarfield.com/projects/the-lantern-75-hampstead-road/BioIan Rudolph BA (Hons) Arch, Dip (Hons) Arch ARB RIBA, is a Director at Marks Barfield Architects in London UK. A qualified architect since 1995, Ian began his career in Germany designing energy efficient mass-timber buildings. Today, he oversees a talented team delivering bespoke, low-carbon projects across the UK and internationally.Marks Barfield Architects, winner of over 100 awards, works across education, arts, culture, workplace, residential, and infrastructure sectors, advancing sustainable and circular design principles. Previously, Ian led major projects at Sheppard Robson, including Santander's London HQ and research facilities for Imperial College London, GSK, and MRC. His focus now is on integrating regenerative design into every facet of architectural practice

MRC careens on though November of 1968, with Fantastic Four 80, Captain Marvel 7, Sub-Mariner 7, and Marvel Super-Heroes 17 featuring the Black Knight! Fun fact: A Choice Not an Ecch-O is a reference to a book by Phillis Shlafley, of all people! Check it out!

- Nvidia, Corning, big optical fiber deal - Optical computing - New MRC RDMA on Ethernet fabrics - MRC vs RoCEv2 and Infiniband - AMD strengths in GPUs and CPUs - Ocean wave energy for data centers [audio mp3="https://orionx.net/wp-content/uploads/2026/05/HPCNB_20260511.mp3"][/audio] The post HPC News Bytes – 20260511 appeared first on OrionX.net.

In this episode of Fraudology, host Karisse Hendrick is joined by a guest she has been trying to bring back to the show for years: Holly Sandberg, a veteran leader in fraud operations, Americas Advisory Board at MRC and the former Director of Trust and Safety at Reverb. As the industry grapples with the rapid rise of Generative AI, Holly and Karisse cut through the "robot takeover" anxiety to provide a grounded, expert perspective on the future of fraud leadership.The conversation explores the evolving mechanics of AI in trust and safety, detailing why the "human element" remains the ultimate force multiplier for technical models. Holly shares why senior fraud leadership cannot be replaced by LLMs, noting that the critical "domain expertise" required to manage sophisticated fraud—and spot model drift—is not found in open-source data.We also explore the "hot topics" dominating the fraud landscape today:The AI Visibility Strategy: Why volunteering for AI steering committees and working cross-functionally is the best way to prove your indispensability to leadership.Hallucinations and Data Gaps: A deep dive into the "bias toward certainty" in AI, featuring a hilarious yet cautionary example of "pizza fraud" hallucinations and the risks of depending on LLMs for math and complex policy.Career Resilience in a Changing Market: Tactical advice on navigating layoffs, the "quiet rehiring" trend, and how to pitch your value for a promotion by focusing on what you will do, rather than just what you've done.

MRC delves into November 1968 with Amazing Spider-Man 66, Daredevil 46, Thor 158, X-Men 50, and the Incredible Hulk 109. Explore with us the power of great inking and the peril of poor inking! Check it out!

Les journalistes et experts de RFI répondent également à vos questions sur des Afghans coincés au Qatar, un recours déposé à l'UA contre la révision constitutionnelle au Cameroun et la flotte moustique iranienne. Tirs contre Donald Trump : comment l'assaillant a-t-il percé la sécurité présidentielle ?  Alors que Donald Trump avait jusqu'à maintenant refusé de prendre part au traditionnel dîner annuel des correspondants de la présidence, sa première participation tourne au drame. Des coups de feu ont retenti au Hilton de Washington, où se tenait la cérémonie, juste après le discours de bienvenue. Des tirs visant le président américain qui a rapidement été évacué. Comment l'assaillant a-t-il pu s'approcher si près de Donald Trump avec une arme lors de ce gala normalement sécurisé ? Cet événement va-t-il entraîner des mesures de sécurité plus strictes ?  Avec Guillaume Naudin, présente la chronique « La fabrique du monde » sur RFI.      États-Unis : quel sort pour les Afghans coincés au Qatar ?   Près de 1 100 Afghans qui ont travaillé avec l'armée américaine sont aujourd'hui coincés au Qatar. Alors que l'administration de l'ancien président, Joe Biden, avait promis de les accueillir sur le sol américain, l'administration de Donald Trump cherche maintenant à les envoyer dans un pays d'Afrique subsaharienne. Parmi ces pays, figurent la RDC avec laquelle les États-Unis viennent de signer un accord migratoire. Qui sont exactement ces Afghans ? Pourquoi sont-ils actuellement bloqués au Qatar ? Comment Washington justifie-t-il son refus de rapatrier les Afghans sur le sol américain comme l'avait promis Biden ?  Avec Nicolas Rocca, journaliste au service international de RFI.      Cameroun : pourquoi l'opposition dénonce une révision constitutionnelle « illégale » ?  Au Cameroun, le parti d'opposition, le Mouvement pour la renaissance du Cameroun (MRC) de Maurice Kamto, a « saisi les instances compétentes de l'Union africaine (UA) » pour contester la révision constitutionnelle adoptée par le gouvernement camerounais au début du mois d'avril. Pourquoi le MRC dénonce-t-il un « coup d'État constitutionnel » ?  Maurice Kamto a-t-il des chances d'être entendu par l'UA ? Avec Stéphane Akoa, analyste politique pour la Fondation Paul Ango Ela.      Iran : pourquoi la « flotte moustique » inquiète les Américains ?  Alors que les négociations entre Washington et Téhéran n'ont toujours pas repris au Pakistan, la menace iranienne en mer prend de l'ampleur. La raison : leur « flotte moustique ». De quoi s'agit-il exactement ? En quoi pourrait-il peser dans les discussions avec les États-Unis ? Avec Dominique Trinquand, ancien chef de la mission militaire française auprès des Nations Unies.

Another one LIVE from the MRC 2026 show floor in Las Vegas, this episode breaks down the high-stakes battle against digital deception with Super.com's Allen Newton and the Joe Midtlyng from Incognia. Uncover why an incredible 90% of digital goods fraud might actually originate from your own users and how "fraud as a service" allows anyone to launch massive attacks without technical skills.   From AI deepfakes tricking ID checks to a bold "personal opinion" on how to finally penalize first-party fraudsters, this talk reveals the hidden war happening behind every click. Watch to see how top platforms use agentic tech and device signals to stay ahead of the curve and protect their bottom line.   Special thanks to Incognia for making this episode possbile and providing the cutting-edge technology needed to ground digital identity in the physical world. To learn more about how they utilize persistent device IDs to stay ahead of sophisticated evasion tactics like app reinstalls and factory resets, visit https://www.incognia.com/blog/incognias-network-graph-persistent-device-id-for-faster-fraud-investigations

"The great thing about the MRC is the way merchants come together to talk about the real issues of fraud and risk in an environment where they're not competing with each other."   In this episode of the Payments Corner Jacqueline and Jordan step into the future of fraud prevention with this deep dive into the highlights of MRC Vegas 2026, where industry leaders tackle the explosive rise of Agentic AI and its impact on digital commerce. This episode goes beyond the hype to explore the critical shift from viewing fraud as a purely payments-based problem to recognizing it as an intricate challenge of identity and permissioning. Discover how top merchants are collaborating to dismantle sophisticated "Liar Buyer" schemes and organized fraud rings that utilize "Fraud-as-a-Service" tools to scale policy abuse at an alarming rate. From the nuances of global payment strategies to the strategic implementation of passkeys and AI-driven operations, this discussion reveals the actionable insights needed to protect your platform while maintaining a seamless user experience for good customers.   Special thanks to ⁠Incognia⁠ for sponsoring this episode and providing the cutting-edge technology needed to ground digital identity in the physical world. To learn more about how they utilize persistent device IDs to stay ahead of sophisticated evasion tactics like app reinstalls and factory resets, visit ⁠https://www.incognia.com/blog/incognias-network-graph-persistent-device-id-for-faster-fraud-investigations

We MUST win the war with Iran! Why are Democrats rooting against the USA and our armed forces? It's because they hate Trump so much! Bill is joined by Shiran Nariman who use to life in Iran. She talks about what life was in Iran...and what must be done. Nick Fondacaro from the MRC talks on the conspiracy theories brought up by Candace Owen and Tucker regarding Charlie Kirk. Degan Regas talks Artimis II mission and more. Jeff Crouere wraps up the show LIVE from New Orleans. See omnystudio.com/listener for privacy information.

MRC finishes the (regular) books of October, 1968 with Captain America 106, Iron Man 6, Avengers 57 and Silver Surfer 2! Check them out, and then show your teacher that comics are okay because one of them printed Ozymandias!

In this episode, we dive deep into one of the most critical aspects of maternal health: hypertension and preeclampsia. Joining us is Fran Conti-Ramsden, an NHS Obstetrics and Gynaecology registrar and MRC-funded PhD fellow who is sitting at the fascinating intersection of clinical medicine and data science.Fran shares her expertise on why high blood pressure occurs during pregnancy, the "red flag" symptoms that often go unnoticed, and how she is using AI and real-world data to create a more equitable future for women's healthcare. Whether you are currently expecting, planning a family, or interested in how technology is transforming the NHS, this conversation provides essential medical insights and a look at the cutting edge of FemTech.What We Cover in This Episode:The Root Causes: Understanding the biological triggers of pregnancy-induced hypertension.Red Flags: The specific warning signs—beyond just a headache—that require immediate medical attention.The Impact on Mom and Baby: How high blood pressure affects fetal development and maternal recovery in the postpartum "fourth trimester."Risk Reduction: Practical steps involving nutrition, lifestyle, and medical interventions to manage your risk.The Long-Term Picture: Why a history of preeclampsia matters for your cardiovascular health years down the road.Innovation in Women's Health: How Fran is leveraging Natural Language Processing (NLP) and genomics to predict and improve pregnancy outcomes.Resources & Links:Download: Download the app here https://my.megi.ai/download/Support: Learn more about preeclampsia https://www.kcl.ac.uk/people/frances-conti-ramsdenpreeclampsia symptoms, high blood pressure in pregnancy, gestational hypertension, maternal health, FemTech innovation, Women's health AI, postpartum heart health, pregnancy complications, NHS clinical research, data science in healthcare, MRC clinical fellowship, personalized pregnancy care.www.NewMomTalk.comBuy Me A CoffeeIG: @NewMomTalk.PodcastYouTube: @NewMomTalkMariela@NewMomTalk.comInterested in being a guest? Shoot us an email!- best parenting podcast- best new mom podcast- best podcasts for new moms- best pregnancy podcast- best podcast for expecting moms- best podcast for moms- best podcast for postpartum- best prenatal podcast- best postnatal podcast- best podcast for postnatal moms- best podcast for pregnancy moms- new mom - expecting mom- first time mom

MRC covers more books from October, 1968, including Fantastic Four 79, Nick Fury Agent of SHIELD 5, Dr. Strange 173, Sub-Mariner 6, and Captain Marvel 6! Android-Man Wants the Wonder Gloves! Op Art vs. Pop Tarts! Check it out!

MRC infiltrates October 1968 with Amazing Spider-Man 65, Daredevil 45, Thor 157, X-Men 49 and Incredible Hulk 108, featuring a big artist-tease and a pleasant inking surprise! Check it out!

WMAL GUEST: DAVID BOZELL (President of the Media Research Center) on new MRC studies exposing extreme anti-American bias in late-night comedy coverage of the Iran conflict and a massive 68-to-2 left-wing slant in MSN’s political news aggregation. WEBSITE: MediaResearch.org SOCIAL MEDIA: X.com/theMRC READ: Comedy Shows Joked About U.S. and Allies 94% of the Time in War's First Week Where to find more about WMAL's morning show: Follow Podcasts on Apple Podcasts, Audible, and Spotify Follow WMAL's "O'Connor and Company" on X: @WMALDC, @LarryOConnor, @JGunlock, @PatricePinkfile, and @HeatherHunterDC Facebook: WMALDC and Larry O'Connor Instagram: WMALDC Website: WMAL.com/OConnor-Company Episode: Wednesday, March 11, 2026 / 7 AM HourSee omnystudio.com/listener for privacy information.